Trademark: 90557596
Word
IXAKA
Status Date
Monday, March 4, 2024
Filing Date
Wednesday, March 3, 2021
Published for Opposition
Tuesday, June 7, 2022
Abandoned Date
Monday, March 4, 2024
40 Production of cell lines for use in the manufacture of biopharmaceuticals; Protein fabrication, production, and manufacture for others; Custom manufacture of pharmaceuticals by pharmaceutical compounders; custom manufacture of biopharmaceuticals by pharmaceutical compounders
5 Chemical, analytical and diagnostic reagents for in vivo use for medical purposes; Pharmaceutical preparations for use in the prevention and treatment of cardiovascular diseases, cancer and genetic disorders; Pharmaceutical preparations for the treatment of ophthalmic diseases and conditions, and for the treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders
1 Chemicals for use in science, scientific research and for laboratory use; analytical and diagnostic reagents for in vitro use for scientific or research use
10 Drug delivery devices sold empty, namely, syringes, bags, infusion and injection sets; structural parts, fittings and accessories for all the aforesaid goods
42 Scientific, medical and industrial research and development services in the field of cardiovascular diseases, cancer, genetic disorders, ophthalmic diseases and conditions, inflammation and inflammatory diseases and disorders and metabolic diseases and disorders; clinical research in the field of cardiovascular diseases, cancer and genetic disorders, ophthalmic diseases and conditions, inflammation and inflammatory diseases and disorders and metabolic diseases and disorders; laboratory research in the field of cardiovascular diseases, cancer and genetic disorders, ophthalmic diseases and conditions, inflammation and inflammatory diseases and disorders and metabolic diseases and disorders; research and development of new drugs and clinical products; materials analyzing; chemical analysis; scientific laboratory services; laboratory testing services for scientific research purposes; medical laboratory services; information and advisory services relating to the foregoing, including such services provided on-line from a computer network or the Internet; Research and development services for pharmaceuticals and for the treatment of diseases and injuries; Genetic engineering services for scientific research purposes; Genetic research being scientific research; genetic testing for scientific research purposes; medical and pharmacological research services; research and development in the fields of biotechnology, biopharmaceuticals and gene therapy; medical and scientific research, namely, conducting clinical trials for others; Research and development of pharmaceutical preparations
The mark consists of the stylized lettering "IXAKA", all depicted in dark blue with the exception of the top half of the letter "X", which is depicted in light blue; a light blue dot is positioned above the letter "X" to create a schematic human form; all of the aforementioned being shown on a white background, with the color white being used to designate transparent portions of the drawing to illustrate a contrasting background.
The color(s) dark blue and light blue is/are claimed as a feature of the mark.
Mar 4, 2024
Abandonment Notice E-Mailed - No Use Statement Filed
Mar 4, 2024
Abandonment - No Use Statement Filed
Aug 4, 2023
Notice Of Approval Of Extension Request E-Mailed
Aug 2, 2023
Sou Extension 2 Granted
Aug 2, 2023
Sou Extension 2 Filed
Aug 2, 2023
Sou Teas Extension Received
Dec 14, 2022
Notice Of Approval Of Extension Request E-Mailed
Dec 12, 2022
Sou Extension 1 Granted
Dec 12, 2022
Sou Extension 1 Filed
Dec 12, 2022
Sou Teas Extension Received
Aug 2, 2022
Noa E-Mailed - Sou Required From Applicant
Jun 7, 2022
Official Gazette Publication Confirmation E-Mailed
Jun 7, 2022
Published For Opposition
May 18, 2022
Notification Of Notice Of Publication E-Mailed
Apr 29, 2022
Electronic Record Review Complete
Apr 1, 2022
On Hold - Electronic Record Review Required
Mar 29, 2022
Approved For Pub - Principal Register
Mar 28, 2022
Teas/Email Correspondence Entered
Mar 28, 2022
Correspondence Received In Law Office
Mar 26, 2022
Assigned To Lie
Mar 23, 2022
Teas Response To Office Action Received
Sep 26, 2021
Notification Of Non-Final Action E-Mailed
Sep 26, 2021
Non-Final Action E-Mailed
Sep 26, 2021
Non-Final Action Written
Sep 25, 2021
Assigned To Examiner
Jun 3, 2021
Notice Of Design Search Code E-Mailed
Jun 2, 2021
New Application Office Supplied Data Entered
Mar 6, 2021
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
